Format

Send to

Choose Destination
Cancer Lett. 2011 Apr 1;303(1):29-38. doi: 10.1016/j.canlet.2011.01.002.

Inhibition of topoisomerase IIα: novel function of wedelolactone.

Author information

1
Department of Experimental Biology, Faculty of Science, Masaryk University, Czech Republic. pbenes@sci.muni.cz

Abstract

The naturally occurring coumestan wedelolactone has been previously shown to reduce growth of various cancer cells. So far, the growth-suppressing effect of wedelolactone has been attributed to the inhibition of the NFκB transcription factor and/or androgen receptors. We found that wedelolactone suppressed growth and induced apoptosis of androgen receptor-negative MDA-MB-231 breast cancer cells at concentrations that did not inhibit the NFκB activity. The cells responded to wedelolactone by the S and G2/M phase cell cycle arrest and induction of the DNA damage signaling. Wedelolactone interacted with dsDNA and inhibited the activity of DNA topoisomerase IIα. We conclude that wedelolactone can act as growth suppressor independently of NFκB and androgen receptors.

PMID:
21315506
DOI:
10.1016/j.canlet.2011.01.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center